Targeting histone deacetylases in pancreatic ductal adenocarcinoma

Journal of Cellular and Molecular Medicine

Volumn 14, Issue 6 A, 2010, Pages 1255-1263

  Schneider, Günter ^a   Krämer, Oliver H ^b   Fritsche, Petra ^a   Schüler, Susanne ^a   Schmid, Roland M ^a   Saur, Dieter ^a  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^b FRIEDRICH SCHILLER UNIVERSITY JENA   (Germany)

Author keywords

Apoptosis; Cell cycle; HDAC; HDAC inhibitors; Pancreatic cancer; Therapy

Indexed keywords

HISTONE DEACETYLASE; HISTONE DEACETYLASE INHIBITOR;

APOPTOSIS; ARTICLE; CELL PROLIFERATION; DRUG EFFECT; ENZYMOLOGY; HUMAN; METABOLISM; METASTASIS; PANCREAS CARCINOMA; PANCREAS TUMOR; PATHOLOGY; CARCINOMA, PANCREATIC DUCTAL; DRUG EFFECTS; PANCREATIC NEOPLASMS;

APOPTOSIS; CARCINOMA, PANCREATIC DUCTAL; CELL PROLIFERATION; HISTONE DEACETYLASE INHIBITORS; HISTONE DEACETYLASES; HUMANS; NEOPLASM METASTASIS; PANCREATIC NEOPLASMS;

EID: 77955150176     PISSN: 15821838     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1582-4934.2009.00974.x     Document Type: Article

References (55)

1. Eckel F, Schneider G, Schmid RM. Pancreatic cancer: a review of recent advances. Expert opinion on investigational drugs. 2006, 15:1395-410.
2. Schneider G, Siveke JT, Eckel F. Pancreatic cancer: basic and clinical aspects. Gastroenterology. 2005, 128:1606-25.
3. Moore MJ, Goldstein D, Hamm J. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol. 2007, 25:1960-6.
4. Richards DA, Boehm KA, Waterhouse DM. Gemcitabine plus CI-994 offers no advantage over gemcitabine alone in the treatment of patients with advanced pancreatic cancer: results of a phase II randomized, double-blind, placebo-controlled, multicenter study. Ann Oncol. 2006, 17:1096-102.
5. Yang XJ, Seto E. The Rpd3/Hda1 family of lysine deacetylases: from bacteria and yeast to mice and men. Nat Rev Mol Cell Biol. 2008, 9:206-18.
6. Haberland M, Montgomery RL, Olson EN. The many roles of histone deacetylases in development and physiology: implications for disease and therapy. Nat Rev Genet. 2009, 10:32-42.
7. Luo J, Nikolaev AY, Imai S. Negative control of p53 by Sir2alpha promotes cell survival under stress. Cell. 2001, 107:137-48.
8. Ouaissi M, Cabral S, Tavares J. Histone deacetylase (HDAC) encoding gene expression in pancreatic cancer cell lines and cell sensitivity to HDAC inhibitors. Cancer Biol Ther. 2008, 7:523-31.
9. Spange S, Wagner T, Heinzel T. Acetylation of non-histone proteins modulates cellular signalling at multiple levels. Int J Biochem Cell Biol. 2009, 41:185-98.
10. Buchwald M, Krämer OH, Heinzel T. HDACi-targets beyond chromatin. Cancer Lett. 2009, 280:160-7.
11. Witt O, Deubzer HE, Milde T. HDAC family: what are the cancer relevant targets. Cancer Lett. 2009, 277:8-21.
12. Glozak MA, Seto E. Histone deacetylases and cancer. Oncogene. 2007, 26:5420-32.
13. Marks PA. Discovery and development of SAHA as an anticancer agent. Oncogene. 2007, 26:1351-6.
14. Xu WS, Parmigiani RB, Marks PA. Histone deacetylase inhibitors: molecular mechanisms of action. Oncogene. 2007, 26:5541-52.
15. Bolden JE, Peart MJ, Johnstone RW. Anticancer activities of histone deacetylase inhibitors. Nat Rev Drug Discov. 2006, 5:769-84.
16. Balasubramanian S, Verner E, Buggy JJ. Isoform-specific histone deacetylase inhibitors: the next step. Cancer Lett. 2009, 280:211-21.
17. Marks PA, Xu WS. Histone deacetylase inhibitors: potential in cancer therapy. J Cell Biochem. 2009, 107:600-8.
18. Weichert W. HDAC expression and clinical prognosis in human malignancies. Cancer Lett. 2009, 280:168-76.
19. Miyake K, Yoshizumi T, Imura S. Expression of hypoxia-inducible factor-1alpha, histone deacetylase 1, and metastasis-associated protein 1 in pancreatic carcinoma: correlation with poor prognosis with possible regulation. Pancreas. 2008, 36:e1-9.
20. Fritsche P, Seidler B, Schüler S. HDAC2 mediates therapeutic resistance of pancreatic cancer cells via the BH3-only protein NOXA. Gut. 2009, 58:1399-409.
21. Ouaissi M, Sielezneff I, Silvestre R. High histone deacetylase 7 (HDAC7) expression is significantly associated with adenocarcinomas of the pancreas. Ann Surg Oncol. 2008, 15:2318-28.
22. Donadelli M, Costanzo C, Faggioli L. Trichostatin A, an inhibitor of histone deacetylases, strongly suppresses growth of pancreatic adenocarcinoma cells. Mol Carcinog. 2003, 38:59-69.
23. Niculescu AB, Chen X, Smeets M. Effects of p21(Cip1/Waf1) at both the G1/S and the G2/M cell cycle transitions: pRb is a critical determinant in blocking DNA replication and in preventing endoreduplication. Mol Cell Biol. 1998, 18:629-43.
24. Haefner M, Bluethner T, Niederhagen M. Experimental treatment of pancreatic cancer with two novel histone deacetylase inhibitors. World J Gastroenterol. 2008, 14:3681-92.
25. Kumagai T, Wakimoto N, Yin D. Histone deacetylase inhibitor, suberoylanilide hydroxamic acid (Vorinostat, SAHA) profoundly inhibits the growth of human pancreatic cancer cells. Int J Cancer. 2007, 121:656-65.
26. Sato N, Ohta T, Kitagawa H. FR901228, a novel histone deacetylase inhibitor, induces cell cycle arrest and subsequent apoptosis in refractory human pancreatic cancer cells. Int J Oncol. 2004, 24:679-85.
27. Ryu JK, Lee WJ, Lee KH. SK-7041, a new histone deacetylase inhibitor, induces G2-M cell cycle arrest and apoptosis in pancreatic cancer cell lines. Cancer Lett. 2006, 237:143-54.
28. Schneider G, Reichert M, Saur D. HDAC3 is linked to cell cycle machinery in MiaPaCa2 cells by regulating transcription of skp2. Cell Prolif. 2007, 40:522-31.
29. Arnold NB, Arkus N, Gunn J. The histone deacetylase inhibitor suberoylanilide hydroxamic acid induces growth inhibition and enhances gemcitabine-induced cell death in pancreatic cancer. Clin Cancer Res. 2007, 13:18-26.
30. Saito A, Yamashita T, Mariko Y. A synthetic inhibitor of histone deacetylase, MS-27-275, with marked in vivo antitumor activity against human tumors. Proc Natl Acad Sci USA. 1999, 96:4592-7.
31. Fournel M, Bonfils C, Hou Y. MGCD0103, a novel isotype-selective histone deacetylase inhibitor, has broad spectrum antitumor activity in vitro and in vivo. Mol Cancer Ther. 2008, 7:759-68.
32. Krämer OH, Knauer SK, Zimmermann D. Histone deacetylase inhibitors and hydroxyurea modulate the cell cycle and cooperatively induce apoptosis. Oncogene. 2008, 27:732-40.
33. Natoni F, Diolordi L, Santoni C. Sodium butyrate sensitises human pancreatic cancer cells to both the intrinsic and the extrinsic apoptotic pathways. Biochim Biophys Acta. 2005, 1745:318-29.
34. Ammerpohl O, Trauzold A, Schniewind B. Complementary effects of HDAC inhibitor 4-PB on gap junction communication and cellular export mechanisms support restoration of chemosensitivity of PDAC cells. Br J Cancer. 2007, 96:73-81.
35. Mottet D, Pirotte S, Lamour V. HDAC4 represses p21(WAF1/Cip1) expression in human cancer cells through a Sp1-dependent, p53-independent mechanism. Oncogene. 2009, 28:243-56.
36. Park JH, Jung Y, Kim TY. Class I histone deacetylase-selective novel synthetic inhibitors potently inhibit human tumor proliferation. Clin Cancer Res. 2004, 10:5271-81.
37. Furumai R, Matsuyama A, Kobashi N. FK228 (depsipeptide) as a natural prodrug that inhibits class I histone deacetylases. Cancer Res. 2002, 62:4916-21.
38. Hamacher R, Schmid RM, Saur D. Apoptotic pathways in pancreatic ductal adenocarcinoma. Mol Cancer. 2008, 7:64.
39. Gahr S, Ocker M, Ganslmayer M. The combination of the histone-deacetylase inhibitor trichostatin A and gemcitabine induces inhibition of proliferation and increased apoptosis in pancreatic carcinoma cells. Int J Oncol. 2007, 31:567-76.
40. Moore PS, Barbi S, Donadelli M. Gene expression profiling after treatment with the histone deacetylase inhibitor trichostatin A reveals altered expression of both pro- and anti-apoptotic genes in pancreatic adenocarcinoma cells. Biochim Biophys Acta. 2004, 1693:167-76.
41. Donadelli M, Costanzo C, Beghelli S. Synergistic inhibition of pancreatic adenocarcinoma cell growth by trichostatin A and gemcitabine. Biochim Biophys Acta. 2007, 1773:1095-106.
42. Garcia-Morales P, Gomez-Martinez A, Carrato A. Histone deacetylase inhibitors induced caspase-independent apoptosis in human pancreatic adenocarcinoma cell lines. Mol Cancer Ther. 2005, 4:1222-30.
43. Bug G, Ritter M, Wassmann B. Clinical trial of valproic acid and all-trans retinoic acid in patients with poor-risk acute myeloid leukemia. Cancer. 2005, 104:2717-25.
44. Bots M, Johnstone RW. Rational combinations using HDAC inhibitors. Clin Cancer Res. 2009, 15:3970-7.
45. Frew AJ, Johnstone RW, Bolden JE. Enhancing the apoptotic and therapeutic effects of HDAC inhibitors. Cancer Lett. 2009, 280:125-33.
46. Piacentini P, Donadelli M, Costanzo C. Trichostatin A enhances the response of chemotherapeutic agents in inhibiting pancreatic cancer cell proliferation. Virchows Arch. 2006, 448:797-804.
47. Olive KP, Jacobetz MA, Davidson CJ. Inhibition of Hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer. Science. 2009, 324:1457-61.
48. Bai J, Demirjian A, Sui J. Histone deacetylase inhibitor trichostatin A and proteasome inhibitor PS-341 synergistically induce apoptosis in pancreatic cancer cells. Biochem Biophys Res Commun. 2006, 348:1245-53.
49. Nawrocki ST, Carew JS, Pino MS. Aggresome disruption: a novel strategy to enhance bortezomib-induced apoptosis in pancreatic cancer cells. Cancer Res. 2006, 66:3773-81.
50. Munster P, Marchion D, Bicaku E. Phase I trial of histone deacetylase inhibition by valproic acid followed by the topoisomerase II inhibitor epirubicin in advanced solid tumors: a clinical and translational study. J Clin Oncol. 2007, 25:1979-85.
51. Fulda S. Modulation of TRAIL-induced apoptosis by HDAC inhibitors. Curr Cancer Drug Targets. 2008, 8:132-40.
52. Chun SG, Zhou W, Yee NS. Combined targeting of histone deacetylases and hedgehog signaling enhances cytoxicity in pancreatic cancer. Cancer Biol Ther. 2009, 8:1328-39.
53. Kasperczyk H, Baumann B, Debatin KM. Characterization of sonic hedgehog as a novel NF-kappaB target gene that promotes NF-kappaB-mediated apoptosis resistance and tumor growth in vivo. FASEB J. 2009, 23:21-33.
54. von Burstin J, Eser S, Paul MC. E-cadherin regulates metastasis of pancreatic cancer in vivo and is suppressed by a SNAIL/HDAC1/HDAC2 repressor complex. Gastroenterology. 2009, 137:361-71.
55. Thiery JP, Sleeman JP. Complex networks orchestrate epithelial-mesenchymal transitions. Nat Rev Mol Cell Biol. 2006, 7:131-42.